Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Oral 6.25 mg, 12.5 mg or 25 mg once daily in phase 2 pharmacology studies
Trials compared hormonal endpoints with testosterone gel; these are research arms rather than approved labelling.
View sourceReports include 25 mg orally daily for one month or longer, and 12.5 mg two to three times weekly
These are self-reports rather than authorised schedules. One observation combined 25 mg daily with tesamorelin and cannot establish an interaction; raw/peptide-education/pe-tesamorelin.md:3887-3913.
View sourceOral quantities cluster around 12.5 mg daily within a reported 6.25-25 mg daily range, with 6.25 mg every other day used as a lower starting and maintenance point and 12.5 mg twice weekly also described; one report reached total testosterone near 960 on 12.5 mg daily and another a roughly 50 percent testosterone rise in four weeks on 12.5 mg twice weekly
Forum provenance from an authenticated archive with usernames omitted. Enclomiphene is discussed as an oral SERM, kept separate from clomiphene, and one report noted daily dosing hurt libido while every-other-day resolved it. The archive repeatedly cautions that grey-market vendors may ship clomiphene instead, urging independent testing. Community provenance, not controlled dose finding; the route is oral throughout.
View sourceEvidence summary
An oral selective oestrogen receptor modulator studied for secondary hypogonadism. It is not a peptide and remains unapproved in major markets.
Protocol basis
The protocol summary reports oral dose arms from controlled endocrine studies and separates hormonal surrogate outcomes from approved treatment guidance.
Community provenance (Peppys)
An authenticated research-forum archive records oral enclomiphene quantities clustering around 12.5 mg daily within a reported 6.25-25 mg range, with 6.25 mg every other day used as a lower starting and maintenance point and 12.5 mg twice weekly also described. Reports include total testosterone near 960 on 12.5 mg daily and a roughly 50 percent rise in four weeks on twice-weekly dosing, alongside a note that daily dosing reduced libido for one subject while every-other-day did not. The archive keeps enclomiphene distinct from clomiphene and repeatedly warns that grey-market vendors may supply clomiphene instead, so independent testing is urged. Usernames are omitted and figures are logged as community provenance without endorsement.
What remains uncertain
Authorised use, long-term patient-centred benefit, rare harms and the role relative to established care remain unsettled.